Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ARDELYX, INC.ARDX · Entity 4972 | Director | June 16, 2026 | June 18, 2026 |
| NOVAVAX INCNVAX · Entity 4632 | Director | June 18, 2026 | June 23, 2026 |
| Opus Genetics, Inc.IRD · Entity 5892 | Director | April 20, 2026 | April 22, 2026 |
| Sagimet Biosciences Inc.SGMT · Entity 5273 | Director | July 18, 2023 | July 20, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ARDELYX, INC.
Report date June 16, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 439,998 |
Reported balance
After 2026-06-16 transaction · row 1
1 source rowRow 1 · 2026-06-16 · Grant · Acquired 26,455 · Balance 439,998 F1: Restricted stock units ("RSUs"). The Reporting Person is entitled to receive one (1) share of Common Stock for each one (1) RSU upon the vesting thereof. The RSUs were issued pursuant to the Issuer's Non-Employee Director Compensation Program. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.67 · Expires 2036-06-16 | Direct | 39,715 |
Reported balance
After 2026-06-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-16 · Grant · Acquired 39,715 · Balance 39,715 F2: The option was issued pursuant to the Issuer's Non-Employee Director Compensation Program. F3: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units ("RSUs"). The Reporting Person is entitled to receive one (1) share of Common Stock for each one (1) RSU upon the vesting thereof. The RSUs were issued pursuant to the Issuer's Non-Employee Director Compensation Program.
F2: The option was issued pursuant to the Issuer's Non-Employee Director Compensation Program.
F3: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date.
NOVAVAX INC
Report date June 18, 2026 · Filed June 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 47,370 |
Reported balance
After 2026-06-20 transaction · row 1
1 source rowRow 1 · 2026-06-20 · Exercise / conversion · Acquired 18,880 · Balance 47,370 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.13 · Expires 2036-06-18 | Direct | 21,270 |
Reported balance
After 2026-06-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-18 · Grant · Acquired 21,270 · Balance 21,270 F2: One hundred percent (100%) of the shares subject to this option grant under the Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 14,180 |
Reported balance
After 2026-06-18 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-18 · Grant · Acquired 14,180 · Balance 14,180 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. F3: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-20 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-20 · Exercise / conversion · Disposed 18,880 · Balance 0 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. F4: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested on the first anniversary of the June 20, 2025 grant date subject to continued service on the Company's Board of Directors through the vesting date |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock.
F2: One hundred percent (100%) of the shares subject to this option grant under the Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date.
F3: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date.
F4: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested on the first anniversary of the June 20, 2025 grant date subject to continued service on the Company's Board of Directors through the vesting date
Opus Genetics, Inc.
Report date April 20, 2026 · Filed April 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 343,022 |
Reported balance
After 2026-04-20 transaction · row 1
1 source rowRow 1 · 2026-04-20 · Grant · Acquired 24,367 · Balance 343,022 F1: Represents a grant of restricted stock units which vest upon the earlier of the one (1) year anniversary of the grant date or the day prior to the Issuer's next annual meeting of stockholders occurring after the grant date, subject to the Reporting Person's continuing service through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a grant of restricted stock units which vest upon the earlier of the one (1) year anniversary of the grant date or the day prior to the Issuer's next annual meeting of stockholders occurring after the grant date, subject to the Reporting Person's continuing service through the vesting date.
Sagimet Biosciences Inc.
Report date July 18, 2023 · Filed July 20, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.05 · Expires 2025-03-09 | Direct | 0 |
Reported balance
After 2023-07-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-07-18 · Disposition to issuer · Disposed 1,976 · Balance 0 F1: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock. F2: The shares underlying this option are fully vested and exercisable as of the date hereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.05 · Expires 2025-03-09 | Direct | 1,976 |
Reported balance
After 2023-07-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-07-18 · Grant · Acquired 1,976 · Balance 1,976 F1: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock. F2: The shares underlying this option are fully vested and exercisable as of the date hereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.36 · Expires 2029-04-27 | Direct | 0 |
Reported balance
After 2023-07-18 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-07-18 · Disposition to issuer · Disposed 23,216 · Balance 0 F1: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock. F2: The shares underlying this option are fully vested and exercisable as of the date hereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.36 · Expires 2029-04-27 | Direct | 23,216 |
Reported balance
After 2023-07-18 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-07-18 · Grant · Acquired 23,216 · Balance 23,216 F1: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock. F2: The shares underlying this option are fully vested and exercisable as of the date hereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.36 · Expires 2031-01-26 | Direct | 0 |
Reported balance
After 2023-07-18 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-07-18 · Disposition to issuer · Disposed 23,839 · Balance 0 F1: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock. F2: The shares underlying this option are fully vested and exercisable as of the date hereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.36 · Expires 2031-01-26 | Direct | 23,839 |
Reported balance
After 2023-07-18 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-07-18 · Grant · Acquired 23,839 · Balance 23,839 F1: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock. F2: The shares underlying this option are fully vested and exercisable as of the date hereof. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock.
F2: The shares underlying this option are fully vested and exercisable as of the date hereof.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 20, 2026 Filed Jun 23, 2026 23:58 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionRestricted Stock Units · Derivative | 18,880 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-076930 · tm2618639-8_4seq1.xml · derivative · entry 4 Rodgers Richard J · CIK 0001313397 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,880 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. F4 · derivative.exercise_date: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested on the first anniversary of the June 20, 2025 grant date subject to continued service on the Company's Board of Directors through the vesting date F4 · derivative.expiration_date: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested on the first anniversary of the June 20, 2025 grant date subject to continued service on the Company's Board of Directors through the vesting date Read SEC document |
| June 20, 2026 Filed Jun 23, 2026 23:58 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 18,880 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-26-076930 · tm2618639-8_4seq1.xml · nonDerivative · entry 1 Rodgers Richard J · CIK 0001313397 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,370 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 23:58 UTC | NOVAVAX INC NVAX · Entity 4632 | GrantRestricted Stock Units · Derivative | 14,180 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-076930 · tm2618639-8_4seq1.xml · derivative · entry 3 Rodgers Richard J · CIK 0001313397 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,180 Underlying: Common Stock · 14,180 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. F3 · derivative.exercise_date: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date. F3 · derivative.expiration_date: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 23:58 UTC | NOVAVAX INC NVAX · Entity 4632 | GrantStock Option (Right to Buy) · Derivative | 21,270 | $0.00 Strike: $9.13 | $0.00 |
DisclosureSEC source: 0001104659-26-076930 · tm2618639-8_4seq1.xml · derivative · entry 2 Rodgers Richard J · CIK 0001313397 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,270 Underlying: Common Stock · 21,270 shares Expires 2036-06-18 F2 · derivative.exercise_date: One hundred percent (100%) of the shares subject to this option grant under the Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date. Read SEC document |
| June 16, 2026 Filed Jun 18, 2026 20:08 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantStock Option (Right to Buy) · Derivative | 39,715 | $0.00 Strike: $5.67 | $0.00 |
DisclosureSEC source: 0001313397-26-000002 · wk-form4_1781813313.xml · derivative · entry 2 Rodgers Richard J · CIK 0001313397 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,715 Underlying: Common Stock · 39,715 shares Expires 2036-06-16 F2 · shares: The option was issued pursuant to the Issuer's Non-Employee Director Compensation Program. F3 · derivative.exercise_date: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date. Read SEC document |
| June 16, 2026 Filed Jun 18, 2026 20:08 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantCommon Stock | 26,455 | $0.00 | $0.00 |
DisclosureSEC source: 0001313397-26-000002 · wk-form4_1781813313.xml · nonDerivative · entry 1 Rodgers Richard J · CIK 0001313397 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 439,998 F1 · shares: Restricted stock units ("RSUs"). The Reporting Person is entitled to receive one (1) share of Common Stock for each one (1) RSU upon the vesting thereof. The RSUs were issued pursuant to the Issuer's Non-Employee Director Compensation Program. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 20:32 UTC | Opus Genetics, Inc. IRD · Entity 5892 | GrantCommon Stock | 24,367 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-26-001788 · form4.xml · nonDerivative · entry 1 Rodgers Richard J · CIK 0001313397 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 343,022 F1 · shares: Represents a grant of restricted stock units which vest upon the earlier of the one (1) year anniversary of the grant date or the day prior to the Issuer's next annual meeting of stockholders occurring after the grant date, subject to the Reporting Person's continuing service through the vesting date. Read SEC document |
| October 29, 2025 Filed Oct 30, 2025 20:30 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionRestricted Stock Units · Derivative | 3,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-104413 · tm2529852-1_4seq1.xml · derivative · entry 2 Rodgers Richard J · CIK 0001313397 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Restricted Stock Units · 3,800 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. F2 · derivative.exercise_date: The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested or will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the October 29, 2022 grant date, in each case subject to continued employment through such vesting date. F2 · derivative.expiration_date: The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested or will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the October 29, 2022 grant date, in each case subject to continued employment through such vesting date. Read SEC document |
| October 29, 2025 Filed Oct 30, 2025 20:30 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 3,800 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-104413 · tm2529852-1_4seq1.xml · nonDerivative · entry 1 Rodgers Richard J · CIK 0001313397 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,490 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. Read SEC document |
| June 20, 2025 Filed Jun 24, 2025 22:40 UTC | NOVAVAX INC NVAX · Entity 4632 | GrantRestricted Stock Units · Derivative | 18,884 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-062196 · tm2518838-6_4seq1.xml · derivative · entry 2 Rodgers Richard J · CIK 0001313397 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,884 Underlying: Common Stock · 18,884 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. F2 · derivative.exercise_date: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested on the first anniversary of the June 20, 2024 grant date subject to continued service on the Company's Board of Directors through the vesting date. F2 · derivative.expiration_date: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested on the first anniversary of the June 20, 2024 grant date subject to continued service on the Company's Board of Directors through the vesting date. Read SEC document |
| June 20, 2025 Filed Jun 24, 2025 22:40 UTC | NOVAVAX INC NVAX · Entity 4632 | GrantStock Option (Right to Buy) · Derivative | 28,326 | $6.42 Strike: $6.42 | $181,852.92 |
DisclosureSEC source: 0001104659-25-062196 · tm2518838-6_4seq1.xml · derivative · entry 1 Rodgers Richard J · CIK 0001313397 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,326 Underlying: Common Stock · 28,326 shares Expires 2035-06-20 F3 · derivative.exercise_date: One hundred percent (100%) of the shares subject to this option grant under the Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 20, 2024 grant date subject to continued service on the Company's Board of Directors through the vesting date. Read SEC document |
| June 18, 2025 Filed Jun 24, 2025 00:42 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantStock Option (Right to Buy) · Derivative | 54,059 | $0.00 Strike: $3.61 | $0.00 |
DisclosureSEC source: 0001628280-25-032729 · wk-form4_1750725716.xml · derivative · entry 3 Rodgers Richard J · CIK 0001313397 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,059 Underlying: Common Stock · 54,059 shares Expires 2035-06-18 F3 · shares: The option was issued pursuant to the Issuer's Non-Employee Director Compensation Program. F4 · derivative.exercise_date: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date. Read SEC document |
| June 18, 2025 Filed Jun 24, 2025 00:42 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantCommon Stock | 41,551 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-032729 · wk-form4_1750725716.xml · nonDerivative · entry 2 Rodgers Richard J · CIK 0001313397 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 413,543 F2 · shares: Restricted stock units ("RSUs"). The Reporting Person is entitled to receive one (1) shares of Common Stock for each one (1) RSU upon the vesting thereof. The RSUs were issued pursuant to the Issuer's Non-Employee Director Compensation Program. Read SEC document |
| June 18, 2025 Filed Jun 24, 2025 00:42 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantCommon Stock | 21,468 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-032729 · wk-form4_1750725716.xml · nonDerivative · entry 1 Rodgers Richard J · CIK 0001313397 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 371,992 F1 · shares: The shares were issued pursuant to the Issuer's Non-Employee Director Compensation Program. The Reporting Person elected to receive stock in lieu of cash as permitted under the program. Read SEC document |
| June 12, 2025 Filed Jun 14, 2025 01:40 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionRestricted Stock Units · Derivative | 10,420 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001593968-25-000759 · primary_01.xml · derivative · entry 2 Rodgers Richard J · CIK 0001313397 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,420 shares Expires 2034-06-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 12, 2025 Filed Jun 14, 2025 01:40 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 10,420 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-25-000759 · primary_01.xml · nonDerivative · entry 1 Rodgers Richard J · CIK 0001313397 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,690 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 30, 2025 Filed May 2, 2025 21:09 UTC | Opus Genetics, Inc. IRD · Entity 5892 | GrantStock Option (Right to Buy) · Derivative | 79,592 | $0.00 Strike: $0.95 | $0.00 |
DisclosureSEC source: 0000905148-25-001430 · form4.xml · derivative · entry 2 Rodgers Richard J · CIK 0001313397 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,592 Underlying: Common Stock · 79,592 shares Expires 2035-04-29 F2 · derivative.exercise_date: The option will vest upon the earlier of the one (1) year anniversary of the grant date or the day prior to the Issuer's next annual meeting of stockholders occurring after the grant date, subject to the Reporting Person's continuing service through the vesting date. Read SEC document |
| April 30, 2025 Filed May 2, 2025 21:09 UTC | Opus Genetics, Inc. IRD · Entity 5892 | GrantCommon Stock | 79,504 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-25-001430 · form4.xml · nonDerivative · entry 1 Rodgers Richard J · CIK 0001313397 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 318,655 F1 · shares: Represents a grant of restricted stock units which vest upon the earlier of the one (1) year anniversary of the grant date or the day prior to the Issuer's next annual meeting of stockholders occurring after the grant date, subject to the Reporting Person's continuing service through the vesting date. Read SEC document |
| January 16, 2025 Filed Jan 17, 2025 21:44 UTC | ARDELYX, INC. ARDX · Entity 4972 | Exercise / conversionStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $0.55 | $0.00 |
DisclosureSEC source: 0001628280-25-001849 · wk-form4_1737150282.xml · derivative · entry 2 Rodgers Richard J · CIK 0001313397 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2032-06-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date. Read SEC document |
| January 16, 2025 Filed Jan 17, 2025 21:44 UTC | ARDELYX, INC. ARDX · Entity 4972 | Exercise / conversionCommon Stock | 100,000 | $0.55 | $55,000.00 |
DisclosureSEC source: 0001628280-25-001849 · wk-form4_1737150282.xml · nonDerivative · entry 1 Rodgers Richard J · CIK 0001313397 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 350,524 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 29, 2024 Filed Jan 2, 2025 21:52 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionRestricted Stock Units · Derivative | 3,800 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001593968-25-000012 · primary_01.xml · derivative · entry 2 Rodgers Richard J · CIK 0001313397 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,800 Underlying: Common Stock · 3,800 shares Expires 2032-10-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: One-third (1/3) of the RSUs subject to this grant under the Plan vest on each of the first three (3) anniversaries of the grant date, in each case subject to continued employment through such vesting date. Read SEC document |
| October 29, 2024 Filed Jan 2, 2025 21:52 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 3,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-25-000012 · primary_01.xml · nonDerivative · entry 1 Rodgers Richard J · CIK 0001313397 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,270 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 14, 2024 Filed Jun 17, 2024 22:54 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantStock Option (Right to Buy) · Derivative | 40,243 | $0.00 Strike: $6.35 | $0.00 |
DisclosureSEC source: 0001628280-24-028604 · wk-form4_1718664869.xml · derivative · entry 2 Rodgers Richard J · CIK 0001313397 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,243 Underlying: Common Stock · 40,243 shares Expires 2034-06-14 F2 · shares: The option was issued pursuant to the Issuer's Non-Employee Director Compensation Program. F3 · derivative.exercise_date: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date. Read SEC document |
| June 14, 2024 Filed Jun 17, 2024 22:54 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantCommon Stock | 12,204 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-028604 · wk-form4_1718664869.xml · nonDerivative · entry 1 Rodgers Richard J · CIK 0001313397 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,524 F1 · shares: The shares were issued pursuant to the Issuer's Non-Employee Director Compensation Program. The Reporting Person elected to receive stock in lieu of cash as permitted under the program. Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 20:05 UTC | NOVAVAX INC NVAX · Entity 4632 | GrantRestricted Stock Units · Derivative | 10,420 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001593968-24-000860 · primary_01.xml · derivative · entry 4 Rodgers Richard J · CIK 0001313397 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,420 Underlying: Common Stock · 10,420 shares Expires 2034-06-12 Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 20:05 UTC | NOVAVAX INC NVAX · Entity 4632 | GrantStock Option (Right to Buy) · Derivative | 15,630 | $15.86 Strike: $15.86 | $247,891.80 |
DisclosureSEC source: 0001593968-24-000860 · primary_01.xml · derivative · entry 3 Rodgers Richard J · CIK 0001313397 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,630 Underlying: Common Stock · 15,630 shares Expires 2034-06-12 Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 20:05 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionRestricted Stock Units · Derivative | 6,670 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001593968-24-000860 · primary_01.xml · derivative · entry 2 Rodgers Richard J · CIK 0001313397 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,670 shares Expires 2033-06-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 20:05 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 6,670 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-24-000860 · primary_01.xml · nonDerivative · entry 1 Rodgers Richard J · CIK 0001313397 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,470 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 11, 2024 Filed Jun 13, 2024 21:31 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | GrantStock Option (Right to Buy) · Derivative | 35,181 | $0.00 Strike: $1.72 | $0.00 |
DisclosureSEC source: 0000905148-24-001714 · form4.xml · derivative · entry 2 Rodgers Richard J · CIK 0001313397 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,181 Underlying: Common Stock · 35,181 shares Expires 2034-06-10 F2 · derivative.exercise_date: The option will vest upon the earlier of the one (1) year anniversary of the grant date or the day prior to the Issuer's next annual meeting of stockholders occurring after the grant date, subject to the Reporting Person's continuing service through the vesting date. Read SEC document |
| June 11, 2024 Filed Jun 13, 2024 21:31 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | GrantCommon Stock | 41,143 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-24-001714 · form4.xml · nonDerivative · entry 1 Rodgers Richard J · CIK 0001313397 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 239,151 F1 · shares: Represents a grant of restricted stock units which vest upon the earlier of the one (1) year anniversary of the grant date or the day prior to the Issuer's next annual meeting of stockholders occurring after the grant date, subject to the Reporting Person's continuing service through the vesting date. Read SEC document |
| January 01, 2024 Filed Jan 3, 2024 23:03 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | GrantCommon Stock | 24,762 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-24-000494 · form4.xml · nonDerivative · entry 1 Rodgers Richard J · CIK 0001313397 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 198,008 F1 · price: The Reporting Person was granted shares of common stock in lieu of cash for board services for 2024. The number of shares was determined by dividing (A) the aggregate amount of the retainer to be earned for board services for such period, by (B) the average fair market value of a share of common stock for the 30 consecutive trading days ending on and including the last trading day prior to the grant date (rounded down to the nearest whole share). The average fair market value was $2.81 per share, the average of the closing price of the common stock for the 30 consecutive trading days prior to January 1, 2024. Read SEC document |
| November 01, 2023 Filed Nov 13, 2023 22:42 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | GrantCommon Stock | 35,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-052986 · form4.xml · nonDerivative · entry 1 Rodgers Richard J · CIK 0001313397 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 173,246 F1 · shares: Represents a grant of restricted stock units, which vest on the one-year anniversary of the date of grant. Read SEC document |
| October 29, 2023 Filed Oct 31, 2023 20:43 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionRestricted Stock Units · Derivative | 3,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-053952 · doc4.xml · derivative · entry 2 Rodgers Richard J · CIK 0001313397 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,600 Underlying: Restricted Stock Units · 3,800 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. F2 · derivative.exercise_date: The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested or will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the October 29, 2022 grant date, in each case subject to continued employment through such vesting date. F2 · derivative.expiration_date: The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested or will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the October 29, 2022 grant date, in each case subject to continued employment through such vesting date. Read SEC document |
| October 29, 2023 Filed Oct 31, 2023 20:43 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 3,800 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-053952 · doc4.xml · nonDerivative · entry 1 Rodgers Richard J · CIK 0001313397 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,800 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. Read SEC document |
| July 18, 2023 Filed Jul 20, 2023 20:18 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | GrantStock Option (Right to Buy) · Derivative | 23,839 | $0.00 Strike: $6.36 | $0.00 |
DisclosureSEC source: 0001104659-23-082732 · tm2321276-20_4seq1.xml · derivative · entry 6 Rodgers Richard J · CIK 0001313397 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,839 Underlying: Series A Common Stock · 23,839 shares Expires 2031-01-26 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock. F2 · derivative.exercise_date: The shares underlying this option are fully vested and exercisable as of the date hereof. Read SEC document |
| July 18, 2023 Filed Jul 20, 2023 20:18 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | Disposition to issuerStock Option (Right to Buy) · Derivative | 23,839 | $0.00 Strike: $6.36 | $0.00 |
DisclosureSEC source: 0001104659-23-082732 · tm2321276-20_4seq1.xml · derivative · entry 5 Rodgers Richard J · CIK 0001313397 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,839 shares Expires 2031-01-26 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock. F2 · derivative.exercise_date: The shares underlying this option are fully vested and exercisable as of the date hereof. Read SEC document |
| July 18, 2023 Filed Jul 20, 2023 20:18 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | GrantStock Option (Right to Buy) · Derivative | 23,216 | $0.00 Strike: $6.36 | $0.00 |
DisclosureSEC source: 0001104659-23-082732 · tm2321276-20_4seq1.xml · derivative · entry 4 Rodgers Richard J · CIK 0001313397 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,216 Underlying: Series A Common Stock · 23,216 shares Expires 2029-04-27 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock. F2 · derivative.exercise_date: The shares underlying this option are fully vested and exercisable as of the date hereof. Read SEC document |
| July 18, 2023 Filed Jul 20, 2023 20:18 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | Disposition to issuerStock Option (Right to Buy) · Derivative | 23,216 | $0.00 Strike: $6.36 | $0.00 |
DisclosureSEC source: 0001104659-23-082732 · tm2321276-20_4seq1.xml · derivative · entry 3 Rodgers Richard J · CIK 0001313397 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,216 shares Expires 2029-04-27 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock. F2 · derivative.exercise_date: The shares underlying this option are fully vested and exercisable as of the date hereof. Read SEC document |
| July 18, 2023 Filed Jul 20, 2023 20:18 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | GrantStock Option (Right to Buy) · Derivative | 1,976 | $0.00 Strike: $23.05 | $0.00 |
DisclosureSEC source: 0001104659-23-082732 · tm2321276-20_4seq1.xml · derivative · entry 2 Rodgers Richard J · CIK 0001313397 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,976 Underlying: Series A Common Stock · 1,976 shares Expires 2025-03-09 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock. F2 · derivative.exercise_date: The shares underlying this option are fully vested and exercisable as of the date hereof. Read SEC document |
| July 18, 2023 Filed Jul 20, 2023 20:18 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | Disposition to issuerStock Option (Right to Buy) · Derivative | 1,976 | $0.00 Strike: $23.05 | $0.00 |
DisclosureSEC source: 0001104659-23-082732 · tm2321276-20_4seq1.xml · derivative · entry 1 Rodgers Richard J · CIK 0001313397 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,976 shares Expires 2025-03-09 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock. F2 · derivative.exercise_date: The shares underlying this option are fully vested and exercisable as of the date hereof. Read SEC document |
| June 15, 2023 Filed Jun 16, 2023 22:30 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantStock Option (Right to Buy) · Derivative | 49,237 | $0.00 Strike: $3.92 | $0.00 |
DisclosureSEC source: 0001628280-23-022556 · wk-form4_1686954623.xml · derivative · entry 2 Rodgers Richard J · CIK 0001313397 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,237 Underlying: Common Stock · 49,237 shares Expires 2033-06-15 F2 · shares: The option was issued pursuant to the Issuer's Non-Employee Director Compensation Program. F3 · derivative.exercise_date: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date. Read SEC document |
| June 15, 2023 Filed Jun 16, 2023 22:30 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantCommon Stock | 18,494 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-022556 · wk-form4_1686954623.xml · nonDerivative · entry 1 Rodgers Richard J · CIK 0001313397 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 238,320 F1 · shares: The shares were issued pursuant to the Issuer's Non-Employee Director Compensation Program. The Reporting Person elected to receive stock in lieu of cash as permitted under the program. Read SEC document |
| June 12, 2023 Filed Jun 13, 2023 20:48 UTC | NOVAVAX INC NVAX · Entity 4632 | GrantRestricted Stock Units · Derivative | 6,670 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-036760 · doc4.xml · derivative · entry 2 Rodgers Richard J · CIK 0001313397 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,670 Underlying: Common Stock · 6,670 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Company common stock. F3 · derivative.exercise_date: One hundred percent (100%) of the RSUs subject to this grant under the Plan will vest one (1) year from the Grant Date subject to continued service on the Company's Board of Directors through the vesting date. F3 · derivative.expiration_date: One hundred percent (100%) of the RSUs subject to this grant under the Plan will vest one (1) year from the Grant Date subject to continued service on the Company's Board of Directors through the vesting date. Read SEC document |
| June 12, 2023 Filed Jun 13, 2023 20:48 UTC | NOVAVAX INC NVAX · Entity 4632 | GrantStock Option (Right to Buy) · Derivative | 7,710 | $0.00 Strike: $7.78 | $0.00 |
DisclosureSEC source: 0001209191-23-036760 · doc4.xml · derivative · entry 1 Rodgers Richard J · CIK 0001313397 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,710 Underlying: Common Stock · 7,710 shares Expires 2033-06-12 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to this option grant under the Novavax, Inc. (the "Company") Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan") will vest one (1) year from the June 12, 2023 grant date (the "Grant Date") subject to continued service on the Company's Board of Directors through the vesting date. Read SEC document |
| April 19, 2023 Filed Apr 22, 2023 00:20 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-019675 · form4.xml · nonDerivative · entry 1 Rodgers Richard J · CIK 0001313397 · Director · Interim CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 138,246 F1 · shares: Represents a grant of restricted stock units, which vest on the one-year anniversary of the date of grant. Read SEC document |
| January 11, 2023 Filed Jan 12, 2023 22:34 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | GrantCommon Stock | 20,822 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-23-001514 · form4.xml · nonDerivative · entry 1 Rodgers Richard J · CIK 0001313397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,246 F1 · price: The Reporting Person was granted shares of common stock in lieu of cash for board services for 2023. The number of shares was determined by dividing (A) the aggregate amount of the retainer to be earned for board services for such period, by (B) the average fair market value of a share of common stock for the 30 consecutive trading days ending on and including the last trading day prior to the grant date (rounded down to the nearest whole share). The average fair market value was $3.07 per share, the average of the closing price of the common stock for the 30 consecutive trading days prior to January 11, 2023. Read SEC document |
| October 29, 2022 Filed Nov 1, 2022 21:10 UTC | NOVAVAX INC NVAX · Entity 4632 | GrantRestricted Stock Units · Derivative | 11,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-055080 · doc4.xml · derivative · entry 2 Rodgers Richard J · CIK 0001313397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,400 Underlying: Common Stock · 11,400 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Company common stock. F3 · derivative.exercise_date: The RSUs subject to this grant under the Plan will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the Grant Date, in each case subject to continued service on the Company's Board of Directors through such vesting date. F3 · derivative.expiration_date: The RSUs subject to this grant under the Plan will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the Grant Date, in each case subject to continued service on the Company's Board of Directors through such vesting date. Read SEC document |
| October 29, 2022 Filed Nov 1, 2022 21:10 UTC | NOVAVAX INC NVAX · Entity 4632 | GrantStock Option (Right to buy) · Derivative | 17,095 | $0.00 Strike: $23.02 | $0.00 |
DisclosureSEC source: 0001209191-22-055080 · doc4.xml · derivative · entry 1 Rodgers Richard J · CIK 0001313397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,095 Underlying: Common Stock · 17,095 shares Expires 2032-10-29 F1 · derivative.exercise_date: The shares subject to this option grant under the Novavax, Inc. (the "Company") Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan"), will vest with respect to one-third (1/3) of the shares on each of the first three (3) anniversaries of the October 29, 2022 grant date (the "Grant Date"), in each case subject to continued service on the Company's Board of Directors through such vesting date. Read SEC document |
| October 03, 2022 Filed Oct 4, 2022 13:00 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | OtherSeries B Warrant (right to buy) · Derivative | 3,148 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001140361-22-035953 · form4.xml · derivative · entry 2 Rodgers Richard J · CIK 0001313397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,148 shares Expires 2022-10-04 F1 · derivative.expiration_date: The expiration date of the Series B Warrants occurred on the later of (x) the Reservation Date (as defined in the Series B Warrants) and (y) the date on which the Series B Warrant has been exercised in full. Read SEC document |
| October 03, 2022 Filed Oct 4, 2022 13:00 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | OtherCommon Stock | 3,148 | $0.00 | $0.31 |
DisclosureSEC source: 0001140361-22-035953 · form4.xml · nonDerivative · entry 1 Rodgers Richard J · CIK 0001313397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,424 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.